Katiana Gruppioni

Katiana Gruppioni, MPH has extensive work experience in the pharmaceutical industry, with roles in evidence generation, value demonstration, and real-world evidence. Katiana is currently the Head of Integrated Evidence Generation at Amylyx Pharmaceuticals since 2023. Previously, they worked at bluebird bio from 2016 to 2023, where they held various positions such as Director of Value Demonstration & Real World Evidence, Associate Director of Value Demonstration & Real World Evidence, and Senior Manager of Real World Evidence. Prior to that, they worked at Infinity Pharmaceuticals from 2011 to 2015, focusing on safety and risk management. Katiana began their career at the Boston Children's Hospital in 2006 as a Laboratory Manager and Research Assistant II. Katiana also has experience as a Clinic Monitor at the Addiction Treatment Center of New England and as a Job Coach at the Autism Services Association.

Katiana Gruppioni, MPH, completed their education with the following chronology:

- From 2001 to 2006, they attended Northeastern University and received a Bachelor of Science (BS) degree in Behavioral Neuroscience.

- Katiana then enrolled at Harvard University from 2007 to 2011 and earned a Master of Arts (MA) degree in Biotechnology.

- In 2014, they joined the Boston University School of Public Health, where they pursued a Master of Public Health (MPH) degree with a focus on Epidemiology. Their studies spanned until 2017.

- Lastly, in 2021 and 2022, Katiana Gruppioni joined Tufts University to obtain a Certificate in Health Economics and Outcomes Research.

In summary, their educational journey includes a BS in Behavioral Neuroscience, an MA in Biotechnology, an MPH in Epidemiology, and a Certificate in Health Economics and Outcomes Research.